ClinicalTrials.gg
CompletedNCT06677853Updated Nov 7, 2024

Timolol Maleate Gel for the Treatment of Infantile Hemangioma

A Phase 2/3 interventional study of Timolol Maleate Gel+Placebo and Timolol Maleate Gel in Infantile Hemangioma, sponsored by Auson Pharmaceuticals Inc.. Completed at 8 sites in China. Open to participants aged 35 Days to 150 Days. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by Auson Pharmaceuticals Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Oct 2020, registered Oct 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
35 Days to 150 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hemangioma, Capillary with a site in China — 6 open to participants now, 7 under way, 1 of them phase 3. Hemangioma, Capillary · China.

Started
2020
the only one that year
Phase 2/3
2 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
1 of 12
Auson Pharmaceuticals Inc.

Among the 12 studies in Hemangioma, Capillary with a site in China, this one is the only one that started in 2020, is one of 2 in phase 2/3, and was the 5th registered.

Hemangioma, Capillary

35 studies on the registry are indexed under Hemangioma, Capillary; 6 are open to participants now.

Browse Hemangioma, Capillary studies →

Open to participants now

6 of the 12 studies in Hemangioma, Capillary with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 3 Hemangioma, Capillary studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 35 Days to 150 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hemangioma, Capillary with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety and efficacy of timolol maleate (TM) gel in subjects with superficial infantile hemangioma (IH) in the proliferative phase. The main question it aims to answer is:

  • The primary endpoint (success or failure) assessment was a centralized and independent qualitative assessment based on blinded comparison on B-ultrasonography results and photographs of IH at W24 from baseline.

Researchers will compare TM gel to a placebo (a look-alike substance that contains no drug) to see if TM gel works to treat IH.

Participants will:

  • Take the study drug 3 times daily (once in the morning, noon, and evening, respectively) for 24 weeks.
  • The family members of patients are instructed to bring the patients to the clinic for regular follow-up visits at Week 4 (W4), Week 12 (W12), and Week 24 (W24) of the treatment period.
  • Keep a diary of concomitant medications and adverse events.
03

Conditions studied

  • Infantile Hemangioma

Browse trials for

Keywords

  • superficial
  • proliferating
  • Infantile Hemangioma
  • Timolol Maleate
04

Who can participate

Ages eligible
35 Days to 150 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female infants at the age of 35 \~ 150 days;
  2. Infant subjects with definitive diagnosis of superficial hemangioma requiring treatment based on medical history, clinical manifestations, and imaging examination (B-ultrasonography, CT or MRI) results;
  3. Infant subjects with single hemangioma lesion;
  4. Infant subjects with the maximum hemangioma diameter being ≥ 1 cm but ≤ 10 cm;
  5. Infant subject with CEA ≥ Grade 2; The guardians of the infant subject understood the study contents and risks of study treatment, signed the form (ICF), and were willing to cooperate with the study conduct.

Exclusion criteria

Exclusion Criteria:

  1. Infant subjects who were known to be allergic to or had history of severe allergy to timolol maleate or other β-receptor blockers;
  2. Infant subjects who had previously been treated with systemic, intralesional or topical , vincristine, α-interferon, imiquimod, propranolol, or other β-receptor blockers;
  3. Infant subjects breastfed by mother who was treated with β-receptor blockers, systemic (oral, intravenous or intramuscular) corticosteroids, vincristine or α-interferon while breastfeeding;
  4. Infant subjects who born more than 2 months premature and younger than 60 days old;
  5. Infant subjects who had previously been treated for hemangioma (including surgery, hormonal drugs, laser therapy, etc.);
  6. Infant subjects with more than one type of hemangioma requiring treatment;
  7. Infant subjects with other skin diseases on the hemangioma surface and surrounding skin areas, such as eczema, infantile eczema, etc.
  8. Infant subjects who had atrioventricular block ≥ second-degree, bradycardia (heart rate \< 100 bpm), sinoatrial syndrome, cardiogenic shock, or other congenital cardiac disorders;
  9. Infant subjects who were suffering from respiratory disorders such as bronchial asthma, bronchospasm and pneumonia;
  10. Infant subjects who were suffering from central nervous system disorders, or had symptoms of increased intracranial pressure, or had other underlying diseases that might cause or aggravate infantile hemangioma;
  11. Infant subjects who had systolic blood pressure \< 50 mmHg or diastolic blood pressure \< 30 mmHg;
  12. Infant subjects who received any other drug within 4 weeks prior to screening; Infant subjects with other conditions not suitable for enrollment at the discretion of the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    Group1-Timolol Maleate Gel + Placebo

    56 patients will be randomized to group 1.

    Drug: Timolol Maleate Gel+Placebo

  • Experimental
    Group 2-Timolol Maleate Gel

    56 patients will be randomized to group 2.

    Drug: Timolol Maleate Gel

  • Placebo comparator
    Group 3-Placebo

    56 patients will be randomized to group 3.

    Drug: Placebo

Interventions

  • DrugTimolol Maleate Gel+Placebo

    Subjects were applied with the 0.5% timolol maleate gel at the affected area twice a day, and with the placebo once a day for 24 weeks.

  • Subjects were applied with the 0.5% timolol maleate gel at the affected area 3 times a day for 24 weeks.

  • DrugPlacebo

    Subjects were applied with placebo at the affected area 3 times a day for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Success rate of cure of IH after 24-week treatment.

    Treatment success is defined as complete or almost complete resolution of the patient's IH at W24 compared with baseline. At the time of centralized independent assessment.

    Time frame: 24 weeks

Secondary outcomes

  1. Changes in the hemangioma volume

    Changes in the hemangioma volume from baseline after treatment for 4, 12 and 24 weeks, adopting the estimation formula of IH volume: V = 0.07×(the average of the hemangioma's longest length and width)\^3.

    Time frame: baseline, week 4, 12 and 24

  2. Changes in hemangioma color

    Change in the color of hemangioma after 4, 12, and 24 weeks of treatment, which is assessed by the CEA (Clinician Erythema Assessment) criteria.The color intensity (e.g., no signs of erythema;slight redness;defined redness;marked redness;fiery redness.) of the IH is assessed on a 5 point scale.

    Time frame: baseline, weeks 4, 12 and 24

  3. Complete/almost complete regression rates of IH from baseline after 4 and 12-week treatment.

    At the time of centralized independent assessment.

    Time frame: baseline, weeks 4 and 12

  4. Complete/almost complete resolution rate of IH at each post-baseline visit (Weeks 4, 12, and 24) from baseline.

    On-site qualitative assessment by the investigator of efficacy.

    Time frame: baseline, Weeks 4, 12, and 24

  5. Evolution of IH at each post-baseline visit(Weeks 4, 12, and 24) from baseline.

    Classified into 5 categories: completely/almost completely resolved, improved, stable, aggravated, and not assessable. On-site qualitative assessment by the investigator of efficacy.

    Time frame: baseline, Weeks 4, 12 and 24

  6. Changes in IH at each post-baseline visit(Weeks 4, 12, and 24) compared to the previous visit.

    Classified into 5 categories: complete/almost complete regression, relief, stabilization, exacerbation, and unable to determine. On-site qualitative assessment by the investigator of efficacy.

    Time frame: Baseline, Weeks 4, 12, and 24

07

Study locations

8 sites
  • Beijing Children's Hospital,Capital Medical University
    Beijing, Beijing 100045, China
  • Children's Hospital, Capital Institute of Pediatrics
    Beijing, Beijing 100056, China
  • Children's Hospital of Soochow University
    Suzhou, Jiangsu 215025, China
  • Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai 200011, China
  • Children's Hospital of Shanxi
    Taiyuan, Shanxi 030013, China
  • Chengdu Women's and Children's Central Hospital
    Chengdu, Sichuan 200080, China
  • Kunming Children's Hospital
    Kunming, Yunan 650228, China
  • Children's Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310052, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Jun 2022, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Nov 7, 2024
StartActual
Oct 28, 2020
Primary completionActual
Jun 21, 2022
CompletionActual
Jun 21, 2022
Last update
Nov 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06677853
Lead sponsor
Auson Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
Oct 28, 2020
Primary completion
Jun 21, 2022
Completion
Jun 21, 2022
Last update
Nov 7, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Timolol

Start the discussion